Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Walpar Nutritions's EV-to-EBIT or its related term are showing as below:
NSE:WALPAR's EV-to-EBIT is not ranked *
in the Drug Manufacturers industry.
Industry Median: 16.08 * Ranked among companies with meaningful EV-to-EBIT only.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Walpar Nutritions's Enterprise Value for the quarter that ended in Mar. 2024 was ₹578.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Walpar Nutritions's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹31.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Walpar Nutritions EV-to-EBIT Related Terms
Walpar Nutritions EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Walpar Nutritions's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Walpar Nutritions's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Walpar Nutritions EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Walpar Nutritions's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Walpar Nutritions's EV-to-EBIT falls into.
Walpar Nutritions's current Enterprise Value is ₹316.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Walpar Nutritions's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹31.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Walpar Nutritions (NSE:WALPAR) has a EV-to-EBIT of 10.12 as of Sep. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Walpar Nutritions and its competitors.
Is Walpar Nutritions' EV-to-EBIT too high?
Walpar Nutritions' current EV-to-EBIT is 10.12. The Drug Manufacturers industry median EV-to-EBIT is 16.08. Walpar Nutritions' value of 10.12 is 37.1% below this industry median. Overall, Walpar Nutritions has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Walpar Nutritions' EV-to-EBIT compare to ZTS and VTRS?
Walpar Nutritions' EV-to-EBIT of 10.12 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-EBIT is 16.08. Walpar Nutritions' value of 10.12 is 37.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.08, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Walpar Nutritions's current EV-to-EBIT of 10.12 is 37.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Walpar Nutritions and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Walpar Nutritions's current EV-to-EBIT is 10.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Walpar Nutritions stock overvalued right now?
Walpar Nutritions (NSE:WALPAR) has a current EV-to-EBIT of 10.12. The current EV-to-EBIT is 10.12 and 37.1% below the Drug Manufacturers industry median of 16.08. Walpar Nutritions' overall GF Score™ is 54/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Walpar Nutritions (NSE:WALPAR), the current EV-to-EBIT is 10.12 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Walpar Nutritions Ltd is India-based company, which is engaged in manufacturing and trading of pharmaceutical, nutraceutical, herbal and ayurvedic commodities. It also manufactures various private label/third party brands for different companies across the country and overseas, as well as for their own brand sales. It is a manufacturer of various types of nutraceutical formulation, pharmaceutical ingredients, and pharmaceutical formulations. It specializes in contract manufacturing, raw materials trading, and direct selling. Its portfolio consists of tablets, capsules, powder/sachets, and oral liquids.
54GF Score
Get the complete analysis for NSE:WALPAR
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WALPAR has been successfully added to your 
